Navigation Links
Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
Date:12/19/2007

NEW YORK, Dec. 19 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI) presented preclinical data on ITI-007, its first in class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) at a major medical meeting last week. The Company is developing ITI-007 for the treatment of schizophrenia and other related psychiatric conditions.

In this presentation, ITI-007 was shown to possess a unique pharmacologic profile, unlike any other existing antipsychotic drug. As a dopamine protein phosphorylation modulator, ITI-007 normalizes brain dopamine activity. At much lower doses and concentrations, ITI-007 selectively blocks 5HT2A receptors. Both of these actions are important for antipsychotic drug action.

"We believe the large separation between activity at dopamine and serotonin receptors will allow a personalized approach to patient treatment for schizophrenia providing an ability to 'dial-in' the optimal D2 receptor occupancy on an individual basis. This personalized approach will allow physicians to tailor doses to achieve optimal antipsychotic efficacy without inducing motoric or other side effects," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies.

In vivo, ITI-007 acted as a partial agonist at pre-synaptic dopamine receptors. For example, ITI-007 provoked an intracellular phosphorylation pattern consistent with the activity of a partial agonist at pre-synaptic dopamine receptors, thereby preserving normal dopamine metabolism. Furthermore, in the prefrontal cortex, a brain region profoundly affected in patients with schizophrenia, ITI-007's effects on extracellular concentrations of dopamine were consistent with a partial dopamine agonist profile.

The Company's presentation demonstrated ITI-007 also has an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disorders.

ITI's CNSProfile(TM) has shown, u
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
6. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LONDON , May 24, 2013 ... non-invasive administration for systemic delivery of therapeutic agents has ... the inhalation drug delivery showing significant promise. The crucial ... of a delivery device play a major role in ... been made in the development of new formulation techniques ...
(Date:5/23/2013)... 24 de mayo de 2013  Volcano Corporation ... y fabricante de herramientas de precisión para terapia ... de la enfermedad vascular periférica y coronaria, anunció ... Ad enosine V asodilator I ndependent ... la sesión de ensayo clínico hot line late ...
(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering.   A portion of the proceeds will be used ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... VIEW, Calif., Dec. 12, 2011  IRIDEX Corporation (Nasdaq: ... clinical study(1) compiled over 10 years demonstrates the safety ... macular edema (DME) without the retina tissue damage associated ... Centers for Disease Control and Prevention, DME, a swelling ...
... Mylan Inc. (Nasdaq: MYL ) today announced ... Pharma, L.P., Mylan,s fully integrated specialty pharmaceutical business. ... professional experience in strategic product launches, marketing, commercialization, sales ... president and chief executive officer of MiddleBrook Pharmaceuticals. In ...
Cached Medicine Technology:10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema 210-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema 3Mylan Names John Thievon President of Dey Pharma 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 A recent study ... of America dreads the upcoming bathing suit season. Almost 138 ... the weather heats up due to weight issues and a ... mercury rises. PharmaCo Labs recommends that those anxious about ... PhenObestin 37.5 as part of an overall effort to improve ...
(Date:5/24/2013)... myMEDholiday.com, a popular medical tourism portal which ... important medical travel destinations in Asia, has added a ... ensure a safe and successful trip for anyone planning ... tips on cost-savings, how to find the appropriate doctors ... wealth other essential advice. , A top-level marketing representative ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... May 24, 2013 This week is ... and their efforts to provide the best emergency care ... of this week is also to educate the public ... of survival. Citizens are the first link, and a ... proper bystander CPR after a cardiac arrest can triple ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Patients hospitalized for ... if they,re admitted on Mondays or in the morning, ... of stay are highest among heart failure patients admitted ... researchers, who are scheduled to present their findings Saturday ... Failure Association of the European Society of Cardiology. ...
Breaking Medicine News(10 mins):Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 2Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 3Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2
... ... expertise in turnarounds and improving hospital profitability joins StatCom in a strategic partnership program that ... ... addition of Tom Brunelle FACHE, MBA, to the StatCom team. Previously Brunelle served as EVP ...
... , , , , , , , , ... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a leading China ... of the acquisition of buildings and land use,rights. The total consideration ... ), which will be financed from working capital. The,initial payment of ...
... ... connectivity combo solution to accelerate time-to-market for handset manufacturers to deliver interoperable sport, ... ... 15, 2010 -- ANT Wireless, a division of Dynastream Innovations Inc. (ANT) and ...
... ... has become the company’s Vice President of Product Services. Among his responsibilities, Randy will ... Notification Network, White Pine’s flagship personal health record solution. , ... (PRWEB) February 14, 2010 -- White ...
... ... Robert Lukasik has joined the company as Vice President of Sales. Separately, Kardea ... , ... 2010 -- Kardea Nutrition ™ LLC announced today that Robert Lukasik has joined the ...
... issue of the Journal of Clinical Sleep Medicine ... (OSA) report a significantly lower frequency of nightmares than ... OSA suppresses the cognitive experience of nightmare recall. ... nightmare recall decreased linearly as sleep apnea severity increased. ...
Cached Medicine News:Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 2Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 3Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 2Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 4Health News:Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services 2Health News:Kardea Nutrition Adds V.P. Sales, Extends Distribution Network 2Health News:Severe sleep apnea decreases frequency of nightmare recall 2
... This antimicrobial skin cleanser will not leave ... with frequent washings. With persistent Antimicrobial action, ... of microorganisms, including gram-negative and gram-positive bacteria, ... as a 15 second hand wash. The ...
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... Povidone Iodine Prep Pads ... surface pathogens including bacteria, ... yeast. Povidone Iodine is ... wounds or mucus membranes. ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: